诺和锐30强化与诺和灵30R治疗2型糖尿病的临床疗效对比分析

摘要

Objective To analyze and probe into the clinical effects of?the novomix30R and novolin 30R in treatment of type 2 diabetes mellitus. Methods 72 patients with type 2 diabetes mellitus and who accepted treatments in our hospital from 2012 to 2014 were taken as the research objects, and these patients were randomly divided into the control group and the study group, with 36 patients in each group. In the study group, they were treated with thenovomix30R while in the con-trol group, they were treated with the novolin 30R. Then, the changes of HbA1c, FBG and 2 hPBG after treatment of two groups were observed and compared and the the time to reach the standard of blood sugar and the probability of occurrence of hypoglycemia were calculated. Results Outcome After treatment, the study group not only the HbA1c, FBG and 2 hPBG were lower than those in the control group,but also the time of blood glucose and the incidence of hypoglycemia were less than those in the control group, and the difference had statistically significant between the groups(P<0.05). Conclusion The effects ofthe novomix30Rin treatment of patients with type 2 diabetes mellitus are significantly better than the novolin 30R, which should be promoted and applied.%目的：分析并且探讨诺和灵30R与诺和锐30强化医治2型糖尿疾病的临床效果。方法将该院2012年-2014年期间诊治的72例2型糖尿疾病的患者进行研究,并将他们分成研究组与对照组,每组36例。研究组选择诺和锐30强化对患者进行医治,对照组则选择诺和灵30R进行医治。观察并对比两组医治后的HbA1c、FBG和2hPBG的改变,并对血糖达标的时间与发生低血糖的几率进行计算。结果医治后,研究组不仅HbA1c、FBG与2 hPBG都比对照组低,且血糖达标的时间与发生低血糖的几率也比对照组少,组间差异有统计学意义(P<0.05)。结论选择诺和锐30强化对于2型糖尿疾病患者的医治效果要明显好于诺和灵30R,值得在临床中推广及应用。